AssetMark Inc
LCTX icon

AssetMark Inc’s Lineage Cell Therapeutics LCTX Stock Holding History

AssetMark Inc’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9
Closed – – 1589
2021
Q3 		$0 Hold
9
– – ﹤0.01% 1478
2021
Q2 		$0 Hold
9
– – ﹤0.01% 1449
2021
Q1 		$0 Hold
9
– – ﹤0.01% 1450
2020
Q4 		$0 Hold
9
– – ﹤0.01% 1455
2020
Q3 		$0 Hold
9
– – ﹤0.01% 1376
2020
Q2 		$0 Hold
9
– – ﹤0.01% 1371
2020
Q1 		$0 Hold
9
– – ﹤0.01% 1464
2019
Q4 		$0 Sell
9
-2
-18% -$2 ﹤0.01% 1437
2019
Q3 		$0 Buy
11
+2
+22% +$2 ﹤0.01% 1372
2019
Q2 		$0 Hold
9
– – ﹤0.01% 1389
2019
Q1 		$0 Buy
+9
New +$11 ﹤0.01% 1448

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AssetMark Inc's LCTX Position: Q4 2021 in Review

AssetMark Inc sold out of Lineage Cell Therapeutics (LCTX) in Q4 2021, closing a stake of 9 shares.

AssetMark Inc first reported a position in LCTX in Q1 2019 and held it in 11 quarters. The position peaked at $0 in Q3 2021. 124 funds tracked by Wall St. Rank hold LCTX as of Q4 2021.

  • AssetMark Inc reported no remaining Lineage Cell Therapeutics position as of Q4 2021 after selling out during the quarter.
  • AssetMark Inc sold 9 Lineage Cell Therapeutics shares in Q4 2021.
  • AssetMark Inc first reported a position in Lineage Cell Therapeutics in Q1 2019 and held it in 11 quarters.
  • AssetMark Inc's Lineage Cell Therapeutics position peaked at $0 in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2021.

Based on AssetMark Inc's 13F filing for Q4 2021, filed 14 Feb 2022.